Arcturus Therapeutics (ARCT) said Friday the European Commission granted marketing authorization for Kostaive, a self-amplifying mRNA COVID-19 vaccine for individuals aged 18 and above.
The biotechnology company said Kostaive is the first self-amplifying mRNA COVID vaccine to receive European Commission clearance and is currently marketed in Japan against the disease.
Kostaive showed "superior" immunogenicity and maintained antibody levels for up to 12 months post-vaccination compared to traditional mRNA vaccines, the company said.
The company also said that the approval follows a favorable opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency on Dec. 12 and is valid across all European countries.
The company's shares were up 2.1% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。